Filing Flows › Health Care › Stereotaxis (STXS)
Stereotaxis (STXS) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 12, 2026 · Stereotaxis (STXS) Q2 2026 earnings results →
Q2 2026 Revenue down 13% year over year to $7.7M · 58¢ of every $1 of revenue lost · operating margin -59.6%
Stereotaxis made $7.7M in Q2 2026 (-13% Y/Y): Disposables Service and Accessories $6.2M, Systems $1.5M. Operating margin -59.6%, net loss $4.5M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 12, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $7.7M in Q2 2026, down 13% year over year and up 22% from the previous quarter. Disposables Service and Accessories was the largest line at 81% of revenue. Systems lost $1.6M year over year (down 51%), 138% of the total change.
Gross margin was 58.5%, up 6.4 points from Q2 2025. Operating costs exceeded revenue by $4.6M, an operating margin of -59.6%. Operating expenses grew 6% against a revenue fall of 13%. The quarter ended with a net loss of $4.5M, narrower than the previous quarter's $5.9M loss.
Operating cash flow was −$3.7M. Non-cash charges added back $407K of depreciation and amortization and $1.6M of share-based compensation. Working capital and other items used $1.2M. Capital expenditures of $64K exceeded it, leaving free cash flow of −$3.7M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 12, 2026 | $7.7M | -13% | -59.6% | −$4.5M | −$3.7M |
| Q1 2026 | 10-Q | May 13, 2026 | $6.3M | -16% | -95.1% | −$5.9M | −$3.4M |
| Q4 2025 | 10-K | Mar 12, 2026 | $8.6M | +36% | -65.4% | −$5.5M | −$4.0M |
| Q3 2025 | 10-Q | Nov 12, 2025 | $7.5M | -19% | -87.8% | −$6.5M | −$4.2M |
| Q2 2025 | 10-Q | Aug 13, 2025 | $8.8M | +95% | -45.2% | −$3.8M | −$3.7M |
| Q1 2025 | 10-Q | May 13, 2025 | $7.5M | +9% | -79.3% | −$5.8M | −$1.8M |
| Q4 2024 | 10-K | Mar 14, 2025 | $6.3M | +39% | -120.3% | −$7.5M | $1.3M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
About Stereotaxis
Stereotaxis (NYSE: STXS) is a pioneer and global leader in innovative surgical robotics for minimally invasive endovascular intervention. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 150,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.Stereotaxis.com.
In its own words, from its 8-K, filed Aug 11, 2026.
Stereotaxis against its Electromedical & Electrotherapeutic Apparatus peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: -13% against the peers' median +14%. Operating margin: -59.6% against the peers' median 6.3%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| STXS Stereotaxis | Q2 2026 | $7.7M | -13% | -59.6% |
| MDT Medtronic | Q1 FY27 | $9.8B | +14% | 18.1% |
| ITGR Integer Holdings | Q3 2026 | $450M | -4% | 6.3% |
| LIVN LivaNova | Q3 2026 | $393M | +10% | 7.2% |
| CNMD Conmed | Q3 2026 | $336M | -0.7% | 11.1% |
| TMDX TransMedics Group | Q3 2026 | $203M | +41% | 13.9% |
| AXGN Axogen | Q3 2026 | $75.8M | +26% | 1.3% |
| OM Outset Medical | Q3 2026 | $33.6M | +14% | -36.5% |
| CBLL Ceribell | Q3 2026 | $29.3M | +30% | -70.0% |
Source: Stereotaxis 10-Q on SEC EDGAR · CIK 1289340 · Electromedical & Electrotherapeutic Apparatus
13F: who owns STXS and who is buying
More on STXS
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results